Hemorrhagic Fever Renal Syndrome Patient Biomarker Study

Clinical data from 51 patients with Hemorrhagic Fever with Renal Syndrome (HFRS) treated at a single hospital from January 2023 to January 2024. It focuses on soluble thrombomodulin (sTM) levels as a biomarker for disease severity and mortality risk, correlating sTM with SOFA scores and patient outcomes.

Use Cases

• Analyze the correlation between soluble thrombomodulin (sTM) levels and SOFA scores across 51 HFRS patient records.
• Evaluate sTM as a prognostic biomarker by comparing its levels between survivor and non-survivor groups.
• Determine the predictive value of sTM for 28-day mortality risk using the provided ROC curve analysis and cut-off value of 49.98 TU/mL.
• Investigate the variation of sTM levels across different HFRS phases (febrile, hypotensive, oliguria-dipuria) and disease subtypes (mild, moderate, severe, critical).

Strengths

• Includes data from 51 HFRS patients, providing a focused clinical cohort.
• Contains biomarker (sTM) measurements correlated with established severity scores (SOFA) and patient survival outcomes.
• Data covers a defined one-year time range from January 2023 to January 2024.

Limitations

• Small sample size of 51 patients limits statistical power and generalizability of findings.
• Data is from a single hospital's Infectious Diseases Department, which may introduce geographic or institutional bias.
• The dataset is small in scale at 36.3 KB, indicating limited scope and number of variables.

Provenance

Source

Infectious Diseases Department of the Second Affiliated Hospital of Air Force Medical University.

Collection Method

Retrospective analysis of patient medical records.

Time Range

January 2023 to January 2024.

Freshness

Data covers up to January 2024 and was last updated in March 2026.

Geography

Hospital in China (inferred from author affiliation and context).